Previous Close | 0.2561 |
Open | 0.2569 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.2510 - 0.2750 |
52 Week Range | 0.2280 - 2.0800 |
Volume | |
Avg. Volume | 404,518 |
Market Cap | 1.599M |
Beta (5Y Monthly) | 0.48 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4200 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition of Dr. David G. Morgan, a renowned leader in neurodegenerative disease to its Scientific Advisory Board ("SAB") reinforcing the Company's commitment to advancing it's INM-901 program in the treatment of
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease modelVancouver, British Columbia--(Newsfile Corp. - April 16, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced addi
INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal functionMolecular analysis data further explains previously reported observations in behavioral studies on locomotion, memory and cognitionVancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manuf